Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

11086090001

Roche

Calpain Inhibitor I

N-Acetyl-Leu-Leu-norleucinal, synthetic

Synonyma:

Calpain Inhibitor I, n-acetyl-leu-leu-norleucinal, ALLN, Ac-LLnL-CHO, MG-101, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Norleu-al

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C20H37N3O4
Číslo CAS:
Molekulová hmotnost:
383.53
Beilstein/REAXYS Number:
7656053
MDL number:
UNSPSC Code:
12352204
PubChem Substance ID:

Quality Level

assay

98% (chromatographically homogeneous)

form

powder

mol wt

Mr = 383.5

packaging

pkg of 25 mg

manufacturer/tradename

Roche

mp

182 °C

solubility

DMF: 10 mg/mL
ethanol: 10 mg/mL
methanol: 10 mg/mL

storage temp.

2-8°C

SMILES string

[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O

InChI

1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1

InChI key

FMYKJLXRRQTBOR-BZSNNMDCSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

General description

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I and calpain II.

Specificity

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I (requiring 2–75 μM Ca2+ for activation) and calpain II (requiring 200–800 μM) with a Ki-value between 0.12 μM and 0.23 μM. Calpain II is inhibited to a lesser extent than calpain I. Calpain Inhibitor I is also a strong inhibitor of papain and cathepsin B and L. It shows only weak inhibition of cathepsin H and α-chymotrypsin and does not inhibit trypsin. ID50 for 0.02 U platelet calpain is 0.05 μM.

Application

Calpain inhibitor I inhibits calpain, which activates myosin light chain kinase and protein kinase C by partial proteolysis. The inhibitor should be membrane permeable due to low molecular weight and lack of charged residues.
Calpain Inhibitor I is used for western blotting methods.

Quality

Purity: 98% (from C); chromatographically homogeneous

Formula variant

C20H37N3O4

Preparation Note

Working concentration: 0.1 - 10 μM
The suggested starting concentration is 17 μg/ml. This is the concentration at which half maximal inhibition of calpain I is observed.
Working solution: Recommended solvent is DMF, ethanol, or methanol up to 10 mg/ml.
Storage conditions (working solution): -15 to -25 °C
Solutions in DMF, methanol, ethanol are stable for 4 weeks at -15 to -25 °C.

Reconstitution

Soluble in DMF, ethanol, or methanol to 10 mg/ml. For a stock solution, Roche recommends dissolving 1 mg of the inhibitor in 100 μl DMF, methanol, or ethanol. Before use, dilute with water or phosphate buffer (0.1 M, pH 7.5) to desired concentration. Solutions in DMF, ethanol, or methanol are stable for 2 to 3 days at 2 to 8 °C, and approximately 4 weeks at -15 to -25 °C. For best results, prepare solutions fresh before use.

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Erdinç Dursun et al.
Journal of Alzheimer's disease : JAD, 23(2), 207-219 (2010-10-23)
Amyloid-β (Aβ) is the core component of amyloid plaques of Alzheimer's disease (AD). The effects of Aβ include damage to neuronal plasma membrane, disruption of Ca(2+) homeostasis, and alterations of neurotrophic factor levels. The aim of this study was to
Takahisa Hirokawa et al.
International journal of molecular sciences, 22(15) (2021-08-08)
Tauopathies are neurodegenerative diseases characterized by abnormal metabolism of misfolded tau proteins and are progressive. Pathological phosphorylation of tau occurs in the retinal ganglion cells (RGCs) after optic nerve injuries. Cyclin-dependent kinase-5 (Cdk5) causes hyperphosphorylation of tau. To determine the
Sami Salmikangas et al.
Microorganisms, 8(12) (2020-12-10)
The current methods to study the distribution and dynamics of viral RNA molecules inside infected cells are not ideal, as electron microscopy and immunohistochemistry can only detect mature virions, and quantitative real-time PCR does not reveal localized distribution of RNAs.
Duygu Gezen-Ak et al.
PloS one, 6(3), e17553-e17553 (2011-03-17)
Recent studies have suggested that vitamin D can act on cells in the nervous system. Associations between polymorphisms in the vitamin D receptor (VDR), age-dependent cognitive decline, and insufficient serum 25 hydroxyvitamin D(3) levels in Alzheimer's patients and elderly people

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.